Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof
US5852186A · kind A · utility
15Cited by
1References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | Dec 22, 1998 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a recombinant human monoclonal antibody which binds to a discontinuous epitope on the HIV gp120 envelope glycoprotien, blocks the binding of gp120 to the CD4 receptor, and neutralizes a broad range of HIV isolates. The present invention also provides the primary nucleotide and deduced amino acid sequences of the rearranged heavy and light chains of the recombinant monoclonal antibody of the present invention, and a method of screening for antibodies which block binding of envelope glycoprotein to the CD4 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.